Full-gene haplotypes refine CYP2D6 metabolizer phenotype inferences
暂无分享,去创建一个
[1] M Ingelman-Sundberg,et al. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. , 1996, The Journal of pharmacology and experimental therapeutics.
[2] Roderic D. M. Page,et al. TreeView: an application to display phylogenetic trees on personal computers , 1996, Comput. Appl. Biosci..
[3] J. Lafitte,et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. , 1997, Pharmacogenetics.
[4] J. Brockmöller,et al. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.
[5] T Varilo,et al. Molecular genetics of the Finnish disease heritage. , 1999, Human molecular genetics.
[6] S. Henikoff,et al. Predicting deleterious amino acid substitutions. , 2001, Genome research.
[7] G. Kerr,et al. Tricyclic antidepressant overdose: a review , 2001, Emergency medicine journal : EMJ.
[8] J. Kere. Human population genetics: lessons from Finland. , 2001, Annual review of genomics and human genetics.
[9] M. Ingelman-Sundberg,et al. Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity. , 2001, Pharmacogenetics.
[10] L. Bertilsson,et al. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. , 2002, British journal of clinical pharmacology.
[11] S. Henikoff,et al. Accounting for human polymorphisms predicted to affect protein function. , 2002, Genome research.
[12] Steven Henikoff,et al. SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..
[13] Donna Karolchik,et al. The UCSC Genome Browser , 2003, Current protocols in human genetics.
[14] W. Koch. Technology platforms for pharmacogenomic diagnostic assays , 2004, Nature Reviews Drug Discovery.
[15] M Ingelman-Sundberg,et al. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity , 2005, The Pharmacogenomics Journal.
[16] A. Gaedigk,et al. Identification and characterization of novel sequence variations in the cytochrome P4502D6 (CYP2D6) gene in African Americans , 2005, The Pharmacogenomics Journal.
[17] S. Henikoff,et al. Predicting the effects of amino acid substitutions on protein function. , 2006, Annual review of genomics and human genetics.
[18] Gideon Koren,et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother , 2006, The Lancet.
[19] Pardis C Sabeti,et al. Common deletion polymorphisms in the human genome , 2006, Nature Genetics.
[20] A. Sajantila,et al. CYP2D6 and CYP2C19 genotypes and amitriptyline metabolite ratios in a series of medicolegal autopsies. , 2006, Forensic science international.
[21] A. Sajantila,et al. A Fatal Doxepin Poisoning Associated With a Defective CYP2D6 Genotype , 2007, The American journal of forensic medicine and pathology.
[22] Magnus Ingelman-Sundberg,et al. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.
[23] A. Gaedigk,et al. The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype , 2008, Clinical pharmacology and therapeutics.
[24] Wei Duan,et al. Clinical pharmacogenetics and potential application in personalized medicine. , 2008, Current drug metabolism.
[25] Masahiro Hiratsuka,et al. Functional Characterization of 17 CYP2D6 Allelic Variants (CYP2D6.2, 10, 14A–B, 18, 27, 36, 39, 47–51, 53–55, and 57) , 2008, Drug Metabolism and Disposition.
[26] Pekka Ellonen,et al. Genetic markers and population history: Finland revisited , 2009, European Journal of Human Genetics.
[27] Howard S. Smith,et al. Opioid metabolism. , 2009, Mayo Clinic proceedings.
[28] C. Béroud,et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.
[29] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[30] P. Bork,et al. A method and server for predicting damaging missense mutations , 2010, Nature Methods.
[31] G. Jiménez-Sánchez,et al. Resequencing, haplotype construction and identification of novel variants of CYP2D6 in Mexican Mestizos. , 2011, Pharmacogenomics.
[32] J. Miller,et al. Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.
[33] Yongwook Choi,et al. A fast computation of pairwise sequence alignment scores between a protein and a set of single-locus variants of another protein , 2012, BCB.
[34] R. Emsley,et al. Next-generation sequencing of pharmacogenes: a critical analysis focusing on schizophrenia treatment , 2013, Pharmacogenetics and genomics.
[35] I. Adzhubei,et al. Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.
[36] H. Gréen,et al. Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases , 2014, The Pharmacogenomics Journal.
[37] Andres Metspalu,et al. Distribution and Medical Impact of Loss-of-Function Variants in the Finnish Founder Population , 2014, PLoS genetics.
[38] Chunlei Du,et al. Corrigendum to ‘Nanopore-based Fourth-generation DNA Sequencing Technology’ [GPB 144 (2015) – GPB 13/1 (4–16)] , 2015, Genom. Proteom. Bioinform..
[39] Gabor T. Marth,et al. A global reference for human genetic variation , 2015, Nature.
[40] A. Papp,et al. Functional characterization of CYP2D6 enhancer polymorphisms. , 2015, Human molecular genetics.
[41] Yongwook Choi,et al. PROVEAN web server: a tool to predict the functional effect of amino acid substitutions and indels , 2015, Bioinform..
[42] Chunlei Du,et al. Nanopore-based Fourth-generation DNA Sequencing Technology , 2015, Genom. Proteom. Bioinform..
[43] R. Gibbs,et al. Comparison and integration of deleteriousness prediction methods for nonsynonymous SNVs in whole exome sequencing studies. , 2015, Human molecular genetics.
[44] F. Cunningham,et al. The Ensembl Variant Effect Predictor , 2016, Genome Biology.
[45] Jean Amos Wilson,et al. CYP2D6 copy number distribution in the US population , 2016, Pharmacogenetics and genomics.
[46] M. Whirl‐Carrillo,et al. Prediction of CYP2D6 phenotype from genotype across world populations , 2016, Genetics in Medicine.
[47] A. Sajantila,et al. Global genetic variation of select opiate metabolism genes in self-reported healthy individuals , 2017, The Pharmacogenomics Journal.
[48] M. Hayden,et al. The global spectrum of protein-coding pharmacogenomic diversity , 2016, The Pharmacogenomics Journal.